We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+4.56%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.67B
AUM Growth
+$41.2M
Cap. Flow
+$7.87M
Cap. Flow %
0.29%
Top 10 Hldgs %
35.39%
Holding
233
New
11
Increased
50
Reduced
32
Closed
29

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$32.1M
2
ILMN icon
Illumina
ILMN
+$23.5M
3
STE icon
Steris
STE
+$18.5M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$16.2M
5
HUM icon
Humana
HUM
+$15.1M

Top Sells

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$41.9M
2
TMO icon
Thermo Fisher Scientific
TMO
+$31.6M
3
UNH icon
UnitedHealth
UNH
+$29M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$21M
5
CVS icon
CVS Health
CVS
+$20.6M

Sector Composition

Rank Sector Weight
1 Healthcare 95.21%
2 Real Estate 2.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARDX icon
126
Ardelyx
ARDX
$1.21B
$3.19M 0.12%
607,698
– –
INSM icon
127
Insmed
INSM
$21.5B
$3.16M 0.12%
98,387
– –
DCPH
128
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$3.15M 0.12%
61,370
– –
HR
129
DELISTED
Healthcare Realty Trust Incorporated
HR
$3.13M 0.12%
104,024
– –
ZLAB icon
130
Zai Lab
ZLAB
$2.07B
$3.12M 0.12%
37,523
– –
BNTX icon
131
BioNTech
BNTX
$23.3B
$3.02M 0.11%
+43,595
New +$3.13M
PVLA
132
Palvella Therapeutics
PVLA
$2.22B
$3M 0.11%
18,116
– –
VRNA
133
DELISTED
Verona Pharma
VRNA
$2.97M 0.11%
475,402
+222,223
+88% +$1.54M
YMAB
134
DELISTED
Y-mAbs Therapeutics
YMAB
$2.94M 0.11%
76,548
– –
ALKS icon
135
Alkermes
ALKS
$8.32B
$2.82M 0.11%
169,930
– –
KDMN
136
DELISTED
Kadmon Holdings, Inc.
KDMN
$2.8M 0.1%
+714,008
New +$3M
PHG icon
137
Philips
PHG
$26B
$2.68M 0.1%
70,195
+1,395
+2% +$56K
MYOK
138
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$2.63M 0.1%
19,300
– –
ZYME icon
139
Zymeworks
ZYME
$1.73B
$2.61M 0.1%
55,938
– –
COGT icon
140
Cogent Biosciences
COGT
$7.22B
$2.58M 0.1%
+275,794
New +$2.88M
MOR
141
DELISTED
MorphoSys AG American Depositary Shares
MOR
$2.57M 0.1%
81,867
+62,477
+322% +$2.02M
ITCI
142
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$2.42M 0.09%
94,238
– –
MTEM
143
DELISTED
Molecular Templates, Inc.
MTEM
$2.4M 0.09%
14,655
+11,834
+419% +$2.1M
NCNA
144
NuCana
NCNA
$5.58M
$2.38M 0.09%
+92
New +$2.49M
THC icon
145
Tenet Healthcare
THC
$21.1B
$2.37M 0.09%
96,736
– –
XRN
146
Chiron Real Estate Inc
XRN
$464M
$2.36M 0.09%
34,979
– –
PRGO icon
147
Perrigo
PRGO
$1.84B
$2.35M 0.09%
51,224
– –
QURE icon
148
uniQure
QURE
$3.07B
$2.32M 0.09%
63,039
– –
AXSM icon
149
Axsome Therapeutics
AXSM
$11B
$2.25M 0.08%
31,591
– –
BHVN
150
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$2.23M 0.08%
34,277
– –
4 5
6
7 8

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2020 Portfolio in Review

As of Q3 2020, Tekla Capital Management held 233 positions worth $2.67B, up 1.6% from $2.63B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Tekla Capital Management's Q3 2020 filing shows 11 new, 50 increased, 32 reduced and 29 closed positions. Its largest new stake was ChemoCentryx, Inc.: 144,447 shares worth $7.92M. The largest sale was Johnson & Johnson, an estimated $41.9M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 95% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q3 2020 buy was ChemoCentryx, Inc.: 144,447 shares worth $7.92M.
  • Tekla Capital Management added most to AbbVie in Q3 2020, an estimated $32.1M increase.
  • Tekla Capital Management's biggest Q3 2020 reduction was Johnson & Johnson, cutting an estimated $41.9M.
  • Tekla Capital Management fully exited Allogene Therapeutics in Q3 2020, selling an estimated $9.25M.
  • Tekla Capital Management's ten largest holdings make up 35% of its $2.67B portfolio in Q3 2020.
  • Tekla Capital Management opened 11 new positions and closed 29 in Q3 2020.
  • Tekla Capital Management's portfolio value rose 1.6% quarter-over-quarter to $2.67B.

Based on Tekla Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.